Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Operating Leases (2020 - 2025)

IGC Pharma (IGC) has disclosed Operating Leases for 6 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 85.71% to $5000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $5000.0, a 85.71% decrease, with the full-year FY2025 number at $10000.0, down 95.19% from a year prior.
  • Operating Leases was $5000.0 for Q3 2025 at IGC Pharma, down from $7000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $433000.0 in Q2 2021 to a low of $5000.0 in Q3 2025.
  • A 5-year average of $198631.6 and a median of $207000.0 in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: increased 0.48% in 2024, then plummeted 95.19% in 2025.
  • IGC Pharma's Operating Leases stood at $374000.0 in 2021, then crashed by 35.56% to $241000.0 in 2022, then tumbled by 52.28% to $115000.0 in 2023, then plummeted by 89.57% to $12000.0 in 2024, then crashed by 58.33% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Leases are $5000.0 (Q3 2025), $7000.0 (Q2 2025), and $10000.0 (Q1 2025).